Crosslink Between Temozolomide and PD-L1 Immune-Checkpoint Inhibition in Glioblastoma Multiforme

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5308-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Comprehensive Analysis of PD-L1 Expression in Glioblastoma Multiforme

Oncotarget
Oncology
2017English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2020English

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

Using Temozolomide in Newly Diagnosed Glioblastoma Multiforme – A Single-Centre Experience

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2010English

Metformin and Temozolomide, a Synergic Option to Overcome Resistance in Glioblastoma Multiforme Models

Oncotarget
Oncology
2017English

Effect of Combined Anti-Pd-1 and Temozolomide Therapy in Glioblastoma

OncoImmunology
OncologyAllergyImmunology
2018English

Functional Differences Between PD-1+ and PD-1- CD4+ Effector T Cells in Healthy Donors and Patients With Glioblastoma Multiforme

PLoS ONE
Multidisciplinary
2017English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy